

Global Sotrovimab Or Xevudy Market Insights 2025: Key Trends, Market Size, And Growth Forecast

The Business Research Company's Sotrovimab Or Xevudy Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 13, 2025

[/EINPresswire.com/](#) -- What's the Growth Projection for the Sotrovimab or Xevudy Market?

•The sotrovimab or xevudy market is expected to expand from \$XX million in 2024 to \$XX million in 2025.

•It is projected to grow at a compound annual growth rate (CAGR) of XX%.



Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!"

The Business Research Company

•Key drivers for this growth include:

- oIncreasing prevalence of COVID-19
- oRising demand for monoclonal antibody treatments
- oGreater awareness of high-risk patient care
- oIncreased government funding

oCollaborations among pharmaceutical companies

•By 2029, the market is anticipated to reach \$XX million.

•It is estimated to maintain a CAGR of XX% over the forecast period.

•Factors contributing to this growth:

- oEmerging new COVID-19 variants
- oExpanding focus on monoclonal antibody therapies
- oGreater healthcare access in developing regions
- oIncreased government initiatives for pandemic preparedness
- oGrowth in telehealth services for treatment delivery

Get Your Free Sample Market Report:



What's Driving Growth in the Sotrovimab or Xevudy Market?

The primary growth driver for the sotrovimab or xevudy market is the increasing prevalence of COVID-19. The virus, transmitted through respiratory droplets, leads to a range of symptoms from mild fever to severe respiratory complications.

Several factors contribute to the rising number of COVID-19 cases:

- Emergence of new variants
- Declining immunity levels
- Relaxation of restrictions
- Seasonal indoor gatherings
- Uneven vaccine coverage

Sotrovimab or Xevudy plays a crucial role in neutralizing the virus in high-risk patients, reducing the likelihood of severe complications, hospitalization, or death. The growing number of cases is expected to drive demand for these treatments.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report>

Who Are the Key Market Players in the Sotrovimab or Xevudy Market?

The sotrovimab or xevudy market features leading pharmaceutical companies such as GSK plc and Vir Biotechnology Inc. These industry players are investing in research and development, forming strategic collaborations, and expanding production capacities to enhance drug accessibility and maintain a competitive edge.

What's the Latest Trend in the Sotrovimab or Xevudy Market?

A notable trend in the sotrovimab or xevudy market is the rise of strategic partnerships aimed at strengthening research and development efforts, increasing production capabilities, and improving drug availability.

For example, in January 2022, GSK plc, a UK-based pharmaceutical company, partnered with Vir Biotechnology Inc. Through this collaboration, they secured a major agreement with the U.S. government to supply additional doses of sotrovimab, a monoclonal antibody authorized for early COVID-19 treatment. This initiative aligns with the ongoing need for effective therapies as new virus variants continue to emerge.

How Is the Sotrovimab or Xevudy Market Segmented?

The sotrovimab or xevudy market is segmented into the following categories:

1.By Indication:

- oCOVID-19 Early Treatment
- oPost-Exposure Prophylaxis

2.By Distribution Channel:

- oHospital Pharmacies
- oRetail Pharmacies
- oOnline Pharmacies

3.By End User:

- oPediatric
- oAdult
- oGeriatric

What Does the Regional Spread of the Sotrovimab or Xevudy Market Look Like?

In 2024, North America led the sotrovimab or xevudy market. Looking ahead, Asia-Pacific is expected to be the fastest-growing region.

The market report covers key geographical areas, including:

- Asia-Pacific
- Western Europe
- Eastern Europe
- North America
- South America
- Middle East
- Africa

Browse for more similar reports-

Virus Filtration Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/virus-filtration-global-market-report>

Herpes Simplex Virus Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/herpes-simplex-virus-treatment-global-market-report>

Antibody Drug Conjugates Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report>

Learn More About The Business Research Company

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that

delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/793412858>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.